AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins... Read More
Market Exclusivity Case Study: XIFAXAN (rifaximin)
Posted on07 May 2020
Comments0
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in... Read More
Bausch + Lomb – Stada Arzneimittel – Xbrane Biopharma – licensing deal for Lucentis biosimilar
Bausch + Lomb announced an exclusive licensing agreement with Stada Arzneimittel and its development partner Xbrane Biopharma to develop and commercialize a... Read More
Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
Posted on24 Apr 2020
Comments0
ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor... Read More
Evox partnership with Takeda Pharmaceutical for rare disease
Evox Therapeutics Ltd, a leading exosome therapeutics company, announced the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited. The... Read More
New Drug Approval Case Study: USFDA approval of Zeposia, delayed market launch likely due to COVID-19
U.S. Food and Drug Administration (FDA) has approved ZEPOSIA® (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple... Read More
ProBiotix Health has signed a distribution licensing agreement with Velinoff Pharma in Bulgaria
UK-based life sciences business OptiBiotix Health said that its unit ProBiotix Health has signed a licensing agreement with Bulgarian pharmaceutical marketing company... Read More
RIBOMIC – AJU Pharma licensing deal for RBM-007 in age-related macular degeneration
Posted on20 Mar 2020
Comments0
RBOMIC has finalized the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company. This deal is for RBM-007 licensing agreement for... Read More
What is USFDA Emergency Use Authorization (EUA)?
Under Emergency use authorization USFDA allows unapproved medical products (e.g. pharmaceutical, biopharmaceutical, diagostic tests, medical devices etc.) to use in market. This... Read More
AstraZeneca disinvest hypertension medicines to Atnahs Pharma
AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide... Read More